Cargando…

Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket

RAS mutants are major therapeutic targets in oncology with few efficacious direct inhibitors available. The identification of a shallow pocket near the Switch II region on RAS has led to the development of small-molecule drugs that target this site and inhibit KRAS(G12C) and KRAS(G12D). To discover...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallon, Lauren, Khan, Imran, Teng, Kai Wen, Koide, Akiko, Zuberi, Mariyam, Li, Jianping, Ketavarapu, Gayatri, Traaseth, Nathaniel J., O’Bryan, John P., Koide, Shohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618066/ https://www.ncbi.nlm.nih.gov/pubmed/36252024 http://dx.doi.org/10.1073/pnas.2204481119

Ejemplares similares

Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors
por: Akkapeddi, Padma, et al.
Publicado: (2023)

Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants
por: Khan, Imran, et al.
Publicado: (2022)

Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation
por: Sha, Fern, et al.
Publicado: (2023)

Mutations in the α4-α5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association
por: Whaby, Michael, et al.
Publicado: (2022)

Proof of dual-topology architecture of Fluc F(-) channels with monobody blockers
por: Stockbridge, Randy B., et al.
Publicado: (2014)

Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Teng, Kai Wen, et al.
Publicado: (2021)

Atomic structure of the eukaryotic intramembrane Ras methyltransferase ICMT
por: Diver, Melinda M., et al.
Publicado: (2018)

Facile target validation in an animal model with intracellularly expressed monobodies
por: Gupta, Ankit, et al.
Publicado: (2018)

Monobodies and other synthetic binding proteins for expanding protein science
por: Sha, Fern, et al.
Publicado: (2017)

Monobodies as tool biologics for accelerating target validation and druggable site discovery
por: Akkapeddi, Padma, et al.
Publicado: (2021)

Selective Targeting of SH2 Domain–Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies
por: Kükenshöner, Tim, et al.
Publicado: (2017)

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
por: Wojcik, John, et al.
Publicado: (2010)

Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains
por: La Sala, Grégory, et al.
Publicado: (2020)

Monobody adapter for functional antibody display on nanoparticles for adaptable targeted delivery applications
por: Albert, C., et al.
Publicado: (2022)

Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia
por: Oury, Julien, et al.
Publicado: (2021)

Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis
por: Jeng, Hao-Hsuan, et al.
Publicado: (2012)

Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation
por: Ni, Duan, et al.
Publicado: (2017)

Structural basis for inhibition of the drug efflux pump NorA from Staphylococcus aureus
por: Brawley, Douglas N., et al.
Publicado: (2022)

Molecular genetics and cellular events of K-Ras-driven tumorigenesis
por: Jinesh, G G, et al.
Publicado: (2018)

Misshapen Disruption Cooperates with Ras(V12) to Drive Tumorigenesis
por: Kong, Du, et al.
Publicado: (2021)

ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold
por: Posada, Itziar M. D., et al.
Publicado: (2016)

Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo
por: Khan, Imran, et al.
Publicado: (2018)

Dynamic regulation of RAS and RAS signaling
por: Kolch, Walter, et al.
Publicado: (2023)

Evolutionary expansion of the Ras switch regulatory module in eukaryotes
por: Díez, Diego, et al.
Publicado: (2011)

Nucleotide Binding Switches the Information Flow in Ras GTPases
por: Raimondi, Francesco, et al.
Publicado: (2011)

Deconstruction of the Ras switching cycle through saturation mutagenesis
por: Bandaru, Pradeep, et al.
Publicado: (2017)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

Involvement of APC and K-ras mutation in non-polypoid colorectal tumorigenesis
por: Umetani, N, et al.
Publicado: (2000)

Ras Oncogene-Mediated Progressive Silencing of Extracellular Superoxide Dismutase in Tumorigenesis
por: Cammarota, Francesca, et al.
Publicado: (2015)

Ras signaling directs endothelial specification of VEGFR2(+) vascular progenitor cells
por: Kawasaki, Kyoko, et al.
Publicado: (2008)

An ERK1/2‐driven RNA‐binding switch in nucleolin drives ribosome biogenesis and pancreatic tumorigenesis downstream of RAS oncogene
por: Azman, Muhammad S, et al.
Publicado: (2023)

Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody
por: Tanaka, Tomoyuki, et al.
Publicado: (2021)

Lipid Profiles of RAS Nanoclusters Regulate RAS Function
por: Zhou, Yong, et al.
Publicado: (2021)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

Hyperglycemia Promotes K-Ras-Induced Lung Tumorigenesis through BASCs Amplification
por: Micucci, Carla, et al.
Publicado: (2014)

K-Ras stabilization by estrogen via PKCδ is involved in endometrial tumorigenesis
por: Koo, Kyoung-Hwa, et al.
Publicado: (2015)

BTB-Zinc Finger Oncogenes Are Required for Ras and Notch-Driven Tumorigenesis in Drosophila
por: Doggett, Karen, et al.
Publicado: (2015)

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation
por: Sung, Hyeran, et al.
Publicado: (2016)

Peroxiredoxin I is important for cancer-cell survival in Ras-induced hepatic tumorigenesis
por: Han, Bing, et al.
Publicado: (2016)

Acrolein contributes to human colorectal tumorigenesis through the activation of RAS-MAPK pathway
por: Tsai, Hong-Chieh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t45k0ciitalr1tahorbue3p4fh